Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Jan 28, 2023 3:51pm
201 Views
Post# 35252167

RE:RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

RE:RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals
One of the primary take-aways from the 41st Annual JP Morgan Healthcare Conference in rainy San Francisco earlier this month was to expect to see more Big Pharma bolt-on and tuck-in acquisitions of later-stage assets to restock the pipeline as drugs roll off patent, as opposed to mega-mergers or assets that still need significant clinical development. Oncology and immunology will continue to dominate.

This aligns with what has been posted on this message board for the past 9-12 months.

Also the
 Inflation Reduction Act. The effects of the law on prescription drug prices are still top of mind, as companies and investors continue to work out how the rules will alter R&D and investment priorities. This could include prioritizing biologics over small-molecule drugs, given the differing drug negotiation exclusionary periods (13 years versus nine years)—which can determine up to 60 percent of value.

This again was discussed on this message board, particularly in the context of ONCY's biologic agent pelareorep being able extend the 13 years of market exclusivity it would gain through its approval, on to any product that Big Pharma may have that is will be going off-patent. This extended exclusivity would be gained by the soon-to-be 'off-patent' product being combined with pelareorep in a particular indication in a certain cancer, like metastatic breast cancer or advanced pancreactic cancer, for example. 
<< Previous
Bullboard Posts
Next >>